Dashboard
1
The company has declared Negative results for the last 13 consecutive quarters
- INTEREST(Q) At CNY 29.75 MM has Grown at 15.02%
- NET PROFIT(Q) At CNY 56.7 MM has Fallen at -46.47%
- DEBT-EQUITY RATIO (HY) Highest at -8.67 %
2
With ROE of 1.24%, it has a very attractive valuation with a 1.43 Price to Book Value
3
Market Beating performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 30,991 Million (Large Cap)
116.00
NA
2.72%
-0.09
1.24%
1.43
Revenue and Profits:
Net Sales:
301 Million
(Quarterly Results - Mar 2026)
Net Profit:
304 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.83%
0%
11.83%
6 Months
66.91%
0%
66.91%
1 Year
88.66%
0%
88.66%
2 Years
71.19%
0%
71.19%
3 Years
90.99%
0%
90.99%
4 Years
9.25%
0%
9.25%
5 Years
782.62%
0%
782.62%
Andon Health Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-10.58%
EBIT Growth (5y)
-210.52%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
0.09
Tax Ratio
14.26%
Dividend Payout Ratio
31.55%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
109.99%
ROE (avg)
25.58%
Valuation key factors
Factor
Value
P/E Ratio
116
Industry P/E
Price to Book Value
1.43
EV to EBIT
-80.33
EV to EBITDA
-96.62
EV to Capital Employed
1.48
EV to Sales
25.08
PEG Ratio
NA
Dividend Yield
2.72%
ROCE (Latest)
-1.84%
ROE (Latest)
1.24%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
301.50
296.30
1.75%
Operating Profit (PBDIT) excl Other Income
-0.80
-81.20
99.01%
Interest
29.70
25.90
14.67%
Exceptional Items
300.20
862.20
-65.18%
Consolidate Net Profit
304.50
681.70
-55.33%
Operating Profit Margin (Excl OI)
-2.60%
-343.30%
34.07%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 1.75% vs -2.53% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -55.33% vs 2.11% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,364.90
2,588.10
-47.26%
Operating Profit (PBDIT) excl Other Income
-245.80
742.50
-133.10%
Interest
117.60
69.40
69.45%
Exceptional Items
2,109.80
710.90
196.78%
Consolidate Net Profit
2,269.50
1,800.00
26.08%
Operating Profit Margin (Excl OI)
-239.50%
260.60%
-50.01%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is -47.26% vs -18.85% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 26.08% vs 33.41% in Dec 2024
About Andon Health Co., Ltd. 
Andon Health Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






